Hosted on MSN
Novo Nordisk and Hims & Hers Health resolve patent dispute and collaborate on weight loss medicationsNovo Nordisk has resolved its patent infringement lawsuit against telehealth provider Hims & Hers, entering into a collaboration to distribute Novo Nordisk’s weight loss medications through the Hims ...
Hosted on MSN
Canaccord Lowers Hims & Hers Health, Inc. (HIMS) Price Target Patent Amid Dispute and FDA ScrutinyHims & Hers Health, Inc. (NYSE:HIMS) ranks among the most shorted stocks to buy according to analysts. Following Novo Nordisk’s lawsuit against Hims & Hers Health, Inc. (NYSE:HIMS), Canaccord Genuity ...
Hims & Hers announced it will offer generic semaglutide through its direct-to-consumer virtual care platform to eligible customers in Canada, following Novo Nordisk's loss of Canadian patent ...
News broke yesterday that the FDA is proposing to exclude the globally best-selling prescription drug molecules semaglutide, tirzepatide and liraglutide from its 503B bulk list, "finding no clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results